Price Info, Side Effects, Dosage, Compare Cost, Pros & Cons, Reviews by Patients and Customers.

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic
Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent’s fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
Read more on News-Medical-Net